Assembly Biosciences (NASDAQ:ASMB) Receives “Neutral” Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports.

Separately, Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and increased their price target for the company from $2.00 to $35.00 in a report on Friday, September 20th.

Assembly Biosciences Stock Up 4.5 %

Shares of NASDAQ:ASMB opened at $15.38 on Friday. Assembly Biosciences has a 1 year low of $9.12 and a 1 year high of $19.93. The stock’s fifty day moving average price is $16.12 and its 200-day moving average price is $15.59.

Insider Buying and Selling

In related news, major shareholder Alexander Schornstein acquired 10,000 shares of Assembly Biosciences stock in a transaction dated Tuesday, October 8th. The stock was purchased at an average cost of $14.58 per share, for a total transaction of $145,800.00. Following the purchase, the insider now directly owns 703,113 shares of the company’s stock, valued at approximately $10,251,387.54. This trade represents a 1.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 394 shares of company stock valued at $5,894. 5.10% of the stock is owned by insiders.

Institutional Trading of Assembly Biosciences

Several hedge funds have recently bought and sold shares of ASMB. JPMorgan Chase & Co. raised its stake in shares of Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 3,442 shares during the period. Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 131.0% in the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 7,690 shares in the last quarter. FMR LLC raised its stake in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares during the period. Renaissance Technologies LLC lifted its holdings in Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Assembly Biosciences in the second quarter worth approximately $6,421,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.